Biogen and Eisai’s Revised Alzheimer’s Drug Works, but Safety Questions Linger

A new class of Alzheimer’s treatments has proven a commercial disappointment over the past two years, but the Japanese pharmaceutical firm Eisai reported new data late Wednesday that analysts say could boost uptake of the drug it sells with Biogen.

#eisai #biogen